Serum Her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer

Journal of International Medical Research

Volumn 35, Issue 2, 2007, Pages 165-172

  Goksel, G ^a   Taneli, F ^a   Uslu, R ^b   Ulman, C ^a   Dinc, G ^a   Coskun, T ^a   Kandiloglu, A R ^a  

^a CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Early stage breast cancer; Her 2 neu; Serum; Survivin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; SURVIVIN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PROTEIN BLOOD LEVEL;

EID: 34249681862     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500201     Document Type: Article

References (19)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R. Howe HL, et al: Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006; 56: 168-183.
2. Llanes-Fernandez L, R Alvarez-Goyanes RI, Arango-Prado Mdel C, J Alcocer-Gonzalez JM, Mojarrieta JC, Pérez XE: Relationship between IL-10 and tumor markers in breast cancer patients. Breast 2006; 15: 482-489.
3. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
4. Ben-ezra JM, Kornstein MJ, Grimmess MM, Krystal G: Small-cell carcinoma of the lung expresses the Bcl-2 protein. Am J Pathol 1994; 145: 1036-1040.
5. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
6. Tang L, Tron VA. Reed JC. Mah KJ, Krajewska M, Li G, et al: Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865-1871.
7. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
8. Yang L, Cao Z, Yan H, Wood WC: Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63: 6815-6824.
9. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, et al: Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004; 50: 1986-1993.
10. Muller V, Witzel I, Luck HJ, Kohler G, von Minckwitz G, Mobus V, et al: Prognostic and predictive impact of the her-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2004; 86: 9-18.
11. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, et al: In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1999; 81: 489-494.
12. Carney WP, Homer PJ, Petit D, Retos C, Grene R, Zabrecky JR, et al: Detection and quantitation of the human her-2/new oncoprotein. J Tumor Marker Oncol 1991; 6: 53-72.
13. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, et al: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992; 10: 1436-1443.
14. Kong SY, Kang JH, Kwon Y, Kang HS, Chung KW, Kang SH, et al: Serum her-2 concentration in patients with early stage breast cancer. J Clin Pathol 2006; 59: 373-376.
15. Kong SY, Nam BH, Lee KS, Kwon Y. Lee ES, Seong MW, et al: Predicting tissue her-2 status using serum her-2 levels in patients with metastatic breast cancer. Clin Chem 2006; 52: 1510-1515.
16. Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W, et al: Tissue expression and serum levels of the oncoprotein her-2/ neu in 157 early stage breast tumours. Anticancer Res 2005; 25: 1433-1440.
17. Chu JS, Shew JY, Huang CS: Immuno-histochemical analysis of survivin expression in early stage breast cancer. J Formos Med Assoc 2004; 103: 925-931.
18. Kayaselçuk F, Nursal TZ, Polat A, Noyan T, Yildirim S, Tarim A. et al: Expression of survivin, bcl-2. p53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res 2004; 23: 105-112.
19. Ryan BM. Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, et al: Survivin expression in breast cancer predicts clinical outcome and is associated with her-2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006; 17: 597-604.